Chosa - Making headway in precision oncology

Chosa Oncology is a Scandinavian biotech looking to progress the clinical development of its cisplatin-based technology, iCIP, which consists of two core technologies: an AI-powered drug response predictor (DRP) that aims to identify the patients most likely to respond to cisplatin treatment and LiPlaCis, a liposomal cisplatin formulation with potential to improve both the safety and efficacy of conventional cisplatin. iCIP has demonstrated encouraging clinical proof-of-concept data from a Phase...